Mitsubishi Tanabe Pharma Corp. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase (CRBN) binding moiety coupled to disease-associated protein targeting moiety through a linker reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune disease, neurodegeneration and genetic disorders.

The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others.

The U.S. Department of Health and Human Services has patented HIV integrase inhibitors reported to be useful for the treatment of HIV infections.

Angel Pharmaceuticals Co. Ltd. has prepared and tested protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.

Shanghai Yiweikang Pharmaceutical Co. Ltd. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, inflammatory and immunological disorders.

Chengdu Chipscreen Pharmaceutical Ltd. has divulged aminothiophene compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) virus infection.

Shanghai Meiyue Biotech Development Co. Ltd. has discovered MAPK p38 inhibitors reported to be useful for the treatment of arthritis, psoriasis, systemic lupus erythematosus, diabetes, cancer, atherosclerosis and Alzheimer's disease.

Vicore Pharma AB has identified compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of fibrosis, heart failure, pulmonary hypertension, respiratory tract infection, myocardial infarction, pre-eclampsia, autoimmune and chronic kidney disease.

Astrazeneca AB has described transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of cancer, hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, diabetes, epilepsy, multiple sclerosis, osteoarthritis and inflammatory disorders.

Cogent Biosciences Inc. has disclosed compounds acting as fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of achondroplasia, cancer, craniosynostosis, Alzheimer's disease, fibrosis, pulmonary fibrosis, systemic scleroderma (systemic sclerosis) and thanatophoric dysplasia, among others.